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Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease lacking effective therapies. Cell
replacement therapy has been suggested as a promising therapeutic approach for multiple neurodegenerative
diseases, including motor neuron disease. We analyzed expanded mesenchymal stem cells (MSCs) isolated
from sporadic ALS patients and compared them with MSCs isolated from healthy donors. MSCs were
isolated from bone marrow by Percoll gradient and maintained in culture in MSC Medium until the third
passage. Growth kinetics, immunophenotype, telomere length, and karyotype were evaluated during in vitro
expansion. Osteogenic, adipogenic, chondrogenic, and neurogenic differentiation potential were also evalu-
ated. No morphological differences were observed in the MSCs isolated from donors or patients. The cellular
expansion potential of MSCs from donors and patients was slightly different. After three passages, the MSCs
isolated from donors reached a cumulative population doubling higher than from patients but the difference
was not statistically significant. No significant differences between donors or patients were observed in the
immunophenotype analysis. No chromosomal alteration or evidence of cellular senescence was observed in
any samples. Both donor and patient MSCs, after exposure to specific conditioning media, differentiated
into adipocytes, osteoblasts, chondrocytes, and neuron-like cells. These results suggest that extensive in vitro
expansion of patient MSCs does not involve any functional modification of the cells, including chromosomal
alterations or cellular senescence. Hence, there is a good chance that MSCs might be used as a cell-based
therapy for ALS patients.
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INTRODUCTION fects by improving the microenvironment (4), by pro-
ducing neurotrophic factors (9), or by a nonneuronal
environmental change achieved by bone marrow (BM)Amyotrophic lateral sclerosis (ALS) is a rapid and
progressive disease characterized by the selective degen- transplantation (5).
The use of mesenchymal stem cells (MSCs) as a celleration of motor neurons that manifests as a linear de-
cline in muscular function, which eventually leads to pa- therapy to repair central nervous system damage is sup-
ported by the ability of these cells to differentiate intoralysis, speech deficits, and dysphagia. Within 2 to 5
years of clinical onset, death, due to respiratory failure, multiple mesenchymal lineages under controlled in vitro
conditions (23). These cells proliferate in culture, ac-occurs (24). For the vast majority of ALS cases, the fac-
tors triggering focal initiation and then the spread of mo- quiring an attached, well-spread morphology, with a
consistent set of marker proteins on their surface, andtor neuron degeneration in sporadic ALS remain to be
elucidated and there is no drug currently available to can differentiate into neurons and glial cells both in vitro
(11,26,31,32), as recently also reported by our groupcure human motor neuron disease.
Stem cell transplantation might represent a potential (16), and in vivo (2,10,29). Recent studies demonstrate
that the potency of MSCs may also be due to the produc-therapeutic strategy in ALS (20). Bone marrow stem cell
transplantation provides positive clinical outcomes in tion of neurotrophic factors, which promote neuronal
survival (6).different animal models of central nervous system dis-
eases. Transplanted stem cells might exert beneficial ef- Our preliminary data seem to demonstrate that autol-
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ogous MSCs transplanted into the spinal cord of a well- Versviers, Belgium) at 10% of fetal bovine serum (FBS,
Cambrex Bioscience) in 75- or 150-cm2 T-flasks (Greinermonitored group of ALS patients are safe and well toler-
ated (17–19). Bio-One GmbH, Frickenhausen, Germany), and main-
tained at 37°C with an atmosphere of 5% CO2. After 3This study was aimed at analyzing whether MSCs
expanded from donors and from sporadic ALS patients days, the nonadherent cells were removed and the cul-
tures refed every 3–4 days. At confluence, after aboutshowed any differences concerning cell growth, immu-
nophenotype, osteogenic, adipogenic, chondrogenic, and 15 days, the adhered monolayer was detached with tryp-
sin/EDTA (Cambrex Bioscience) for 5 min at 37°C, andneurogenic differentiation potential, telomere length,
and karyotype modifications during in vitro expansion. the trypsin action was blocked with trypsin neutralizing
solution (Cambrex Bioscience) for 5 min at 37°C. The
MATERIALS AND METHODS cells were then seeded at a density of 8,000/cm2 and
Study Subjects detached every 7 days for two to three passages in order
to expand the isolated cells.Eighteen healthy Caucasian donors (4 men and 14
women), who underwent BM collection for a related pa-
Cellular Expansion Analysis of MSCstient, and 24 patients (13 men and 11 women) affected
Cellular expansion growth rate of donor and patientby sporadic ALS enrolled in a study approved by the
MSCs was evaluated by cell count in a Burker ChamberItalian Institute of Health and by the Ethical Committee
at each passage and expressed in terms of populationof the Piedmont Region were analyzed. Inclusion crite-
doubling (PD) using the formula log N/log 2, where Nria were: diagnosis of definite ALS according to the El
is the cell number of the confluent monolayer dividedEscorial revised criteria (3), mild to severe functional
by the initial number of cells seeded, as performed inimpairment at the spinal level, no or mild signs of bulbar
the Stenderup studies (28).involvement, no signs of respiratory failure. Patients and
controls were excluded if they had evidence of any con-
Cytofluorimetric Analysis of MSCs
current illness or were receiving any medications that
The immunophenotype analysis of adherent cells wascould affect bone. Standard therapies were used through-
performed, at each passage, by flow cytometry analysis.out the study.
Around 2–5 × 105 cells were stained for 20 min withThe severity of the disease was evaluated by means
anti-CD45 fluoroisothyocyanate (FITC) and CD14 phy-of ALS Functional Rating Scale (FRS) (30), Norris
coerytrin (PE), hematopoietic surface antigens; CD90-score (22), and Forced Vital Capacity.
FITC, a membrane glycoprotein, also called Thy-1, used
Bone Marrow as a stem cell marker; CD29FITC, the β subunit of the
fibronectin receptor; CD44PE, receptor-III of extracellu-BM was collected from the iliac crest under epidural
lar matrix; CD105PE or endoglin; CD166 and CD106,anesthesia according to the standard procedure (1). Both
cell adhesion molecules (Becton Dickinson, San Jose,donors and patients gave their informed consent to par-
CA, USA), and 0.5 µg/ml of propidium iodide (Sigmaticipate in the study.
Aldrich) for viability analysis. Labeled cells were thor-
Isolation of MSCs oughly washed with PBS 1× and were analyzed on an
Epics XL cytometer (Beckman Coulter, CA, USA) withDonor BM cells were obtained from the unfiltered
BM collection bag (Baxter Healthcare Corporation, IL, the XL2 software program. The percentage of positive
cells was calculated using the cells stained with IgUSA), containing a few milliliters of BM, which was
normally discarded before the BM infusion. The bag FITC/PE as a negative control.
was washed three times with phosphate-buffered saline
Evaluation of MSC Telomere Length(PBS) 1× (Cambrex Biosciences, Verseviers, Belgium)
and the cells were collected at 900 × g for 15 min. A In order to determine senescence during culture, telo-
mere length was analyzed at each passage by Flow Fluo-median number of 885 ml (range 612–1,420) of BM
was harvested from patients and centrifuged at 900 × g rescence In Situ Hybridization (Flow FISH) (25). Two
hundred thousand expanded MSCs were labeled with afor 15 min to discard the anticoagulant medium. Donor
and patient cells were then layered on a Percoll (Sigma telomere-specific conjugated (C3TA2)3 peptide nucleo-
tide acid (PNA) probe (Perseptive Biosystems, Framing-Aldrich, St. Louis, MO, USA) gradient (density: 1.073
g/ml) and centrifuged at 1100 × g for 30 min, according ham, MA) and the same number were analyzed as a con-
trol without a probe. The same number of hemopoieticto a previously reported method (14). The cells in the
interphase were collected, washed twice with PBS 1× stem cells was isolated with an immunomagnetic system
using CD34 microbeads conjugated antibody from BM(200 × g for 10 min), and seeded at a density of
800,000/cm2 in MSC Medium (Cambrex Bioscience, at the moment of collection and used as examples of
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long telomeres. Stained cells were analyzed on a FACS 8,000/cm2 in α-MEM supplemented with 10% horse se-
rum and 10% FBS for 1 week. The cells were then cul-Calibur cytometer (Beckon Dickinson, CA, USA). At
the beginning of each experiment, the fluorescence sig- tured for 3 weeks alternating two different mediums,
according to Pittenger’s method (23): 1) α-MEM sup-nals from four different populations of FITC-labeled mi-
crobeads, ranging from 3,000 to 5,000 molecular equiv- plemented with 1 µM dexamethasone, 0.5 mM isobutyl
methylxanthine, 10 µg/ml insulin, 100 µg/ml indometh-alents of soluble fluorochrome (MESF) (QuantumTM 24
FITC Premix, Flow Cytometry Corporation, IN, USA), acin (all by Invitrogen Corporation) and 10% FBS for
72 h, and 2) α-MEM with 10 µg/ml insulin (Invitrogenwere acquired. The voltage and amplification of the FL1
parameter were set in such a way that blank, 6,288, 12, Corporation) for 24 h. After fixing and permeabilizing
the cells, adipogenic differentiation was demonstrated25, and 26,904 MESF units per bead corresponded to
channel numbers ranging from 10 to 15, 150 to 160, 450 by the accumulation of neutral lipid vesicles by Oil Red
O staining (Sigma Aldrich). Briefly, cells were stainedto 460, and 800 to 820, respectively, in the FL1 channel
on a linear scale. The resulting calibration curve (y = with Oil Red O 0.5% for 15 min, washed in water for
10 min, and the nuclei counterstained with Mayers he-0.029x) was used to convert telomere fluorescence into
MESF units in order to compare the experiment results. matoxylin solution for 10 min.
Chondrogenic differentiation was induced by cultur-
Karyotype Analysis of MSCs ing 250,000 MSCs, collected in pellets, in 15-ml Falcon
tubes in high glucose Dulbecco’s modified Eagle me-Two hundred thousand MSCs were cultivated over-
night in MSC Medium with 100 ng/ml of Colcemid (In- dium (DMEM, Invitrogen Corporation) supplemented
with 10 ng/ml TGF-β3, 100 nM dexamethasone, 50 µg/vitrogen Corporation, Grand Island, NY, USA) to obtain
a sufficient number of metaphases, and then harvested ml ascorbic acid, 100 µg/ml sodium piruvate, 40 µg/ml
prolin, and ITS plus (Invitrogen Corporation) for 3with trypsin/EDTA. The cells were then lysed with hy-
potonic KCl and fixed in a solution of methanol/acetic weeks. The pellets were then included in paraffin and
acid (3:1). Ten metaphases were analyzed after GTG
banding using MackType software (Nikon Corporation,
Japan). Donor MSCs were analyzed at the second pas- Table 1. Patients’ Characteristics
sage, while patient MSCs were analyzed at any culture
passage. ALS-FRS Norris FVC
Patient Sex Age Score Score (%)
In Vitro Differentiation
1 F 36 31 60 51To induce osteogenic differentiation, donor and pa-
2 F 21 26 77 73tient MSCs were cultured in 10-cm2 petri culture dishes 3 M 37 37 91 105
at a density of 8,000/cm2 for 3 weeks in α-MEM supple- 4 M 29 35 82 80
mented with 10 nM dexamethasone, 0.05 mM ascorbic 5 F 51 31 77 95
acid, and 10 mM β-glycerol phosphate (all by Sigma- 6 M 60 38 83 117
Aldrich). The cells were then fixed and permeabilized 7 M 32 33 83 77
with acetone/methanol solution (1:1) for 20 min at 8 F 53 33 76 101
9 M 47 35 84 104−20°C and differentiation was demonstrated by the ac-
10 M 52 39 94 110cumulation of calcium by crystalline hydroxyapatite de-
11 F 58 31 84 125tection with Von Kossa staining (cells were treated in
12 M 57 39 93 1190.5% silver lactate for 25 min, washed in water, and
13 M 47 36 87 93counterstained with nuclear fast red 0.1% for 5 min;
14 M 41 30 80 104Sigma Aldrich). The accumulation of collagen was eval- 15 F 60 26 70 68
uated by Masson Thrichrom Goldner staining (Bio-Optica, 16 F 75 25 70 85
Milan, Italy). Briefly, the cells were treated with Weig- 17 F 48 30 65 82
ert’s iron hematoxylin solution for 10 min and with pic- 18 F 23 16 39 50
ric acid alcoholic solution for 4 min; after washing in 19 M 32 22 44 81
water the cells were stained with Ponceau acid fuchsine 20 M 64 34 75 100
21 M 33 13 28 25according to Masson for 4 min, washed in water, and
22 F 46 33 75 108treated with phosphomolybdic acid solution for 10 min.
23 F 45 26 62 53Then, without washing, collagen was evaluated by light
24 M 36 32 67 100green solution according to Goldner for 5 min.
Adipogenic differentiation was obtained by culturing ALS-FRS: Amyotrophic Lateral Sclerosis-Functional Rating Scale;
FVC: forced vital capacity.MSCs in 10-cm2 petri culture dishes at a density of
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Figure 1. Donor and patient MSC morphology. Phase contrast images of MSC culture after 3 days from the seeding (A1, B1), and
at first (A2, B2) and third passage (A3, B3). The upper panels (A) show donor MSCs and the bottom panels (B) patient MSCs. At
3 days of culture the nonadherent cells were removed but a low contamination of hematopoietic cells persisted and a few foci of
fibroblastic cells were shown. After 15 days from the seeding (first passage) the presence of nonadherent cells was lower and the
formation of the fibroblastic layer was seen until it generated a confluent monolayer. Original magnification 20×.
the cells stained with S-100 antibody (10 µg/ml; Ven- crotubule associated protein (MAP2) (1:50, Chemicon),
and positive cells were compared to total cells labeledtana Medical Systems, Tucson, AZ, USA) recognizing
S-100 protein localized in chondrocytes. with 4′,6-diamidino-2-phenylindole (DAPI).
To induce neural differentiation, we cultured MSCs,
Statistical Analysisfor 3 weeks, in 10-cm2 petri culture dishes at a density
of 8,000/cm2 in Neural Progenitor Maintenance Medium Statistical analysis was performed using a two-way
(NPMM) (Cambrex), a maintenance medium for the repeated-measures ANOVA to compare the two groups
neural progenitor cells containing basal medium supple- of donors and patients.
mented with recombinant human basic fibroblastic growth
factor (hFGF-B), recombinant human epidermal growth RESULTS
factor (hEGF), neural survival factor-1 (NSF-1), and Study Subjectsgentamicin 30 mg/ml and amphotericin 15 µg/ml, as
Eighteen BM samples collected from healthy donorspreviously described (16). Differentiated MSCs were
(4 men and 14 women) with median ages of 31 yearsfixed and permeabilized with acetone/methanol solution
(20–48 years), and 24 samples collected from ALS pa-(1:1) for 20 min at −20°C. Nonspecific binding was
tients (13 men and 11 women) with median ages of 47blocked with 0.1% human albumin (HSA) in PBS. The
years (21–75 years) were analyzed. Nine patientscells were incubated with the primary antibody, then
showed a severe functional impairment of the lowerwith CY3-coupled anti-mouse (1:1000; Immunological
limbs and were unable to walk while the remaining pa-Sciences, Rome, Italy) and FITC-coupled anti-rabbit (1:
tients showed a mild functional impairment of the upper500; Southern Biotechnology, Birmingham, AL, USA)
and lower limbs. None manifested signs of respiratorysecondary antibodies. All incubations were performed
failure. The median duration of the disease from diagno-for 1 h at room temperature. Between each step, the cells
sis was 24 months (6–96 months). The main clinicalwere washed in 1% HSA PBS (Cambrex). The cells
features of patients at the time of recruitment in thewere reacted with antibodies against neuron specific
study are shown in Table 1.enolase (NSE) (1:200, Immunological Sciences) and mi-
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MSC Isolation and Morphology Cellular Expansion Analysis of MSCs
Cumulative PD after three passages was 2.3 ± 1.3 inAfter Percoll gradient centrifugation a median num-
ber of 105 × 106 (40–267) mononuclear cells (MNCs) the MSCs isolated from donors and 1.5 ± 1.3 in patients’
MSCs. In terms of absolute numbers, after three pas-and 989 × 106 (84–2,258) MNCs were obtained from
donors and patients, respectively. During MSC expan- sages, we obtained a mean number of MSCs of 8.04 ×
106 (SD 9.55 × 106) from donor BM and a mean numbersion no morphological differences were observed in the
MSCs isolated from either donors or from patients: ad- of 4.73 × 106 (SD 5.13 × 106) from patient BM from 1 ×
106 initial cells. A median of 70 × 106 patient cellsherent cells were observed in all samples after 3 days of
culture and in the following 15 days (first passage) the (range 7–152 × 106) was obtained after three passages.
The differences were not statistically significant. Nocells rapidly generated a confluent layer possessing an
elongated, fibroblastic shape (Fig. 1). The in vitro ex- correlation between the cellular expansion potential of
MSCs or duration of the disease and functional ratingpanded MSCs showed no bacterial or fungal contamina-
tion. scales was found among the patients.
Figure 2. Growth kinetic curves of donor and patient MSC cultures. Growth kinetics of hMSCs
isolated from donors and patients during the in vitro expansion from the first to the third passages.
The growth rate is expressed as a mean number of cumulative PD (A) and as a mean of absolute
number (B) as a function of time in culture.
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Table 2. Median Values (and Ranges) of Antigen Expression of MSCs Isolated From Donors and Patients and Analyzed at Each Passage
CD45+ CD14+ CD90+ CD106+ CD29+ CD44+ CD166+ CD105+
Donors
Passage 1 15.45% 12.67% 95.85% 23.20% 93.00% 95.40% 67.95% 96.10%
(1.55–29.50) (0.80–32.90) (46.10–98.00) (1.90–75.00) (51.20–98.90) (32.40–99.30) (3.67–78.50) (92.20–98.50)
Passage 2 3.05% 9.08% 94.60% 36.80% 88.30% 97.70% 21.30% 96.70%
(0.10–11.70) (0.13–29.80) (74.30–99.10) (3.88–96.70) (8.72–97.40) (34.50–99.10) (1.62–61.60) (8.16–99.30)
Passage 3 3.59% 5.69% 93.70% 22.05% 91.20% 98.90% 19.00% 93.90%
(0.06–6.61) (0.32–6.90) (74.50–99.30) (2.55–63.10) (1.92–97.30) (30.64–99.60) (1.58–57.00) (68.80–99.70)
Patients
Passage 1 12.00% 7.10% 77.45% 30.10% 75.50% 93.40% 15.30% 77.60%
(1.20–84.40) (0.07–80.00) (2.50–97.00) (1.30–91.00) (20.00–96.80) (31.00–98.90) (1.00–76.00) (13.76–96.30)
Passage 2 8.12% 8.84% 78.60% 40.50% 82.15% 93.20% 16.75% 87.80%
(0.93–35.00) (0.00–40.40) (19.60–93.90) (6.40–93.30) (23.47–98.00) (20.70–99.70) (1.50–70.60) (19.31–98.50)
Passage 3 5.95% 2.95% 90.20% 44.00% 92.80% 94.05% 24.90% 91.95%
(0.00–38.80) (0.00–49.00) (27.50–100.00) (18.00–92.00) (37.20–100.00) (34.80–99.80) (1.00–60.40) (8.00–99.00)
Figure 3. Flow cytometric analysis of donor and patient MSCs at first and third passages. Immunophenotypic features of donor
(A) and patient (B) MSCs at the first (A1, B1) and third (A2, B2) passages of in vitro expansion. The percentage of positive cells
was calculated using the cells stained with Ig FITC/PE as a negative control.
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Figure 3. (continued)
The growth curves, expressed in means of cumulative immunophenotypic features of donor and patient MSCs
are illustrated in Figure 3. Table 2 shows the medianPD and absolute number established for donors and pa-
tients, are given in Figure 2. values and ranges of the antigen expression of MSCs
isolated and analyzed at each passage from donors and
Cytofluorimetric Analysis of MSCs patients. No significant differences between donors and
patients were observed in the immunophenotype analy-During the expansion time, the cells were analyzed at
each passage for the expression of CD45, CD14, CD90, sis; a slight difference was revealed for CD106, an adhe-
sion molecule, although it was not statistically signifi-CD29, CD44, CD105, CD166, and CD106 (Table 2). At
the first passage the MSC cultures isolated from donors cant. Figure 4 shows the trend of the antigen expression
of MSCs isolated from donors and patients, which wereshowed a low contamination of hematopoietic cells (CD45
and CD14), while they showed a high expression of analyzed from the first to the third passage.
CD90, CD29, CD44, and CD105 and a lower expression
Evaluation of Cellular Senescenceof CD106 and CD166 adhesion molecules. At the third
passage donor MSCs were negative for CD45 and Donor and patient MSCs were analyzed for cellular
senescence during the expansion. The mean telomereCD14, and expressed high percentages of CD90, CD29,
CD44, and CD105 and low levels of CD106 and CD166. shortening after three passages was 0.43 kb in donor
MSCs and 0.58 kb in patient MSCs, as shown in TableMSCs isolated from patients, at the first passage, showed
a low contamination of hematopoietic cells (CD45 and 3; this difference was not statistically significant.
CD14) and variable levels of CD90, CD44, CD29,
Karyotype AnalysisCD106, CD166, and CD105. At the third passage, they
expressed lower levels of hematopoietic antigens CD45 Five donor samples were analyzed at the second pas-
sage and no chromosomal alteration was noted. Norand CD14, high levels of CD90, CD29, CD44, and
CD105, and lower levels of CD106 and CD166. The were there any chromosomal alterations at any passages
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Figure 4. Modulation of median values of antigen expression analyzed at each culture passage
during expansion. Cytofluorimetric analysis of MSCs isolated from donors (A) and from patients
(B) during the in vitro expansion from the first to the third passage. The percentage of positive
cells was calculated using the cells stained with Ig FITC/PE as a negative control.
of all the patient MSCs. The karyotype from one donor with chondrogenic differentiating medium the pellets
from donor MSCs and from patient MSCs resulted posi-and from one patient are given as examples in Figure 5.
tive for the presence of S-100 protein (Fig. 6G, H). In
In Vitro Differentiation
Donor and patient MSCs were induced to differenti-
ate into the different lineages. After osteogenic differen-
Table 3. Median of Telomere Length and Telomeretiation, donor and patient MSC samples presented some
Shortening of Human MSCs During In Vitro Expansioncubical cells with crystals, and calcium ossalates were
in Donor and Patient MSCs
evaluated by Von Kossa staining (Fig. 6A, B), while
the accumulation of collagen was evaluated by Masson Shortening:
Trichrome Goldner (Fig. 6C, D). Adipocytes were re- Passage Passage Passage Pass. 1–
vealed as an accumulation of lipid vacuoles: both donor 1 (kb) 2 (kb) 3 (kb) Pass. 3 (kb)
and patient MSCs showed some large, rounded cells
Donors 9.83 9.74 9.40 0.43with intracytoplasmic vacuoles (Fig. 6E,F), which ap-
Patients 8.52 7.63 7.94 0.58peared positive by Oil Red O staining. After 3 weeks
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Figure 5. Karyotype of donor and patient MSC cultures. Giemsa-banded karyotype analysis show-
ing chromosomes of MSCs at the third passage. (A) MSCs isolated from one donor. (B) MSCs
isolated from one patient.
NPMM, MSCs first aggregated in spheres suspended in In order to evaluate whether there were any differ-
ences between the two groups of MSCs, we analyzedthe medium and then formed adherent clusters with cells
with prominent processes, which resulted positive for cellular expansion, immunophenotype profile, viability,
sterility conditions, cellular senescence, and karyotype.NSE (Fig. 6I, J) and MAP-2 (Fig. 6L, M), both in donor
and in patient MSCs. Osteogenic, adipogenic, chondrogenic, and neurogenic
differentiation potential was also evaluated. The in vitro
DISCUSSION cell population was homogeneous with a fibroblastic-
like morphology and no hemopoietic cell contamination.In this work we analyzed the expansion potential of
MSCs isolated from the BM of 18 healthy donors and The in vitro expanded MSCs showed no bacterial or fun-
gal contamination.of 24 patients with definite ALS. MSCs were easily iso-
lated from the BM of both healthy donors and patients. The cellular expansion potential of MSCs from do-
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nors and patients was slightly different. After three pas-
sages, the MSCs isolated from donors reached a higher
cumulative PD than from patients, but the difference
was not statistically significant. The discrepancy be-
tween the two groups may be explained by the different
median ages. In a previous study, in which we expanded
donor MSCs for a median of 18 passages, we demon-
strated that the cell growth of in vitro expanded MSCs
is closely related to the donor’s age (15), which tallies
with other studies reporting a negative correlation be-
tween donor age and MSC proliferative potential (7,21,28).
No correlation between the cellular expansion poten-
tial of MSCs and the duration or expansion potential and
severity of the disease was found among patients. The
discrepancy between the two groups may be explained
by the different ages, as previously demonstrated by our
group (15) and by other studies (7,21,28).
The immunophenotype analysis revealed no signifi-
cant differences between donors and patients for CD106
(vascular cell adhesion molecule 1, VCAM1), an adhe-
sion molecule constitutively expressed by BM stromal
cells that is important for the retention of hematopoietic
precursor cells (HPC) in the hemopoietic organs during
development (27), which seemed higher during expan-
sion in patients’ MSC. Moreover MSCs, both from
healthy donors and from ALS patients, showed multilin-
eage potential when cultivated in different conditioning
media specific for osteogenic, adipogenic, and chondro-
genic differentiation. As reported by Dominici et al. (8),
plastic adhesion in standard culture conditions, the ex-
pression of specific surface markers, and the capability
to differentiate into osteoblasts, adypocytes, and chon-
drocytes are the minimal criteria to define human MSCs.
We also demonstrated that donor and patient MSCs ac-
quired, under specific condition, new morphological
FACING COLUMN
Figure 6. Multilineage differentiation of donor and patient
MSCs into osteoblasts (A, B, C, D), adipocytes (E, F), chon-
drocytes (G, H), and neural-like cells (I, J, L, M). The pres-
ence of calcium oxalates seen with Von Kossa staining showed
the differentiation of either donor (A) and patient (B) MSCs
into the osteoblast lineage. Masson Thrichrom Goldner stain-
ing showed the accumulation of collagen (green) in donor (C)
and patient (D) MSCs. Adipogenesis was indicated by the
presence of neutral lipid vacuoles in donor (E) and in patient
(F) MSCs. Sections from paraffin-embedded pellets after
chondrogenic induction resulted positive for S-100 staining in
all samples analyzed (G, H). Donor MSCs cultured in NPMM
formed adherent clusters with cells showing prominent pro-
cesses that resulted positive for NSE (I) and MAP-2 (L); the
nuclei were counterstained with DAPI (blue). Patient MSCs
displayed the same features (J, M). Original magnification:
10× (G, H), 20× (A, B, C, D, I, L, J, M), and 40× (E, F).
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